Yes the ops move gives less risk to the sp, and makes the company more attractive as a T/O also makes it more attractive to Board purchasing stock prior to an announcement! Trial results have had a high degree of variability thats very true and have bee done on to small a sample IMHO but the nano market cap is small for a company at this stage of devpt They should not worry about FDA approval instead go the European route dueto the plant based product liked by German pharmacies I would be hesitant about holding too much in this as it is extremely speculative so many wonder cancer treatment companies out there!
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held